Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence
This study evaluated the relationship between the retinal nonperfusion area (NPA) presence and the effectiveness of bevacizumab treatment (IVB) in patients with diabetic macular edema (DME). It also tested the prognostic usefulness of ultra-wide-field fluorescein angiography (UWFFA) and OptosAdvance...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6620122 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559762435211264 |
|---|---|
| author | Bogumiła Sędziak-Marcinek Sławomir Teper Elżbieta Chełmecka Adam Wylęgała Mateusz Marcinek Mateusz Bas Edward Wylęgała |
| author_facet | Bogumiła Sędziak-Marcinek Sławomir Teper Elżbieta Chełmecka Adam Wylęgała Mateusz Marcinek Mateusz Bas Edward Wylęgała |
| author_sort | Bogumiła Sędziak-Marcinek |
| collection | DOAJ |
| description | This study evaluated the relationship between the retinal nonperfusion area (NPA) presence and the effectiveness of bevacizumab treatment (IVB) in patients with diabetic macular edema (DME). It also tested the prognostic usefulness of ultra-wide-field fluorescein angiography (UWFFA) and OptosAdvance software for diabetic retinopathy monitoring. Eighty-nine patients with DME with a macular central subfield thickness CST≥250 μm, with (N=49 eyes) and without (N=49 eyes) retinal NPA, underwent nine bevacizumab injections over 12 months. NPA distribution, leakage area distribution, microaneurysm (MA) count, macular CST, diabetic retinopathy severity, and best-corrected visual acuity (BCVA) were assessed. The results show that bevacizumab reduced the macular CST from 420 to 280 μm (p<0.001) and improved BCVA (p<0.001) by about 10 ETDRS letters in both groups of patients. Additionally, the therapy reduced total retinal NPA from 29 (14-36) mm2 to 12 (4-18) mm2 (Me (Q1-Q3); p<0.001) in patients with diagnosed nonperfusion. The effect of the therapy measured with vascular leakage, MA count, BCVArelative, and CSTrelative strongly depended on the zone of the retina and the NPA distribution. We conclude that the bevacizumab treatment had a positive effect on DME and BCVA in both study groups and on the size of retinal NPA in patients with retinal nonperfusion. |
| format | Article |
| id | doaj-art-50a7dc8952c04747af5a36bf83f76115 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-50a7dc8952c04747af5a36bf83f761152025-02-03T01:29:21ZengWileyJournal of Diabetes Research2314-67452314-67532021-01-01202110.1155/2021/66201226620122Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion PresenceBogumiła Sędziak-Marcinek0Sławomir Teper1Elżbieta Chełmecka2Adam Wylęgała3Mateusz Marcinek4Mateusz Bas5Edward Wylęgała6Chair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, PolandChair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, PolandDepartment of Statistics, Department of Instrumental Analysis, Faculty of Pharmaceutical Sciences in Sosnowiec, 41-200 Sosnowiec, Medical University of Silesia, Katowice, PolandHealth Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-728 Katowice, PolandDepartment of Urology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-760 Katowice, PolandFaculty of Biomedical Engineering, Silesian University of Technology, 41-800 Zabrze, PolandChair and Department of Ophthalmology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-760 Katowice, PolandThis study evaluated the relationship between the retinal nonperfusion area (NPA) presence and the effectiveness of bevacizumab treatment (IVB) in patients with diabetic macular edema (DME). It also tested the prognostic usefulness of ultra-wide-field fluorescein angiography (UWFFA) and OptosAdvance software for diabetic retinopathy monitoring. Eighty-nine patients with DME with a macular central subfield thickness CST≥250 μm, with (N=49 eyes) and without (N=49 eyes) retinal NPA, underwent nine bevacizumab injections over 12 months. NPA distribution, leakage area distribution, microaneurysm (MA) count, macular CST, diabetic retinopathy severity, and best-corrected visual acuity (BCVA) were assessed. The results show that bevacizumab reduced the macular CST from 420 to 280 μm (p<0.001) and improved BCVA (p<0.001) by about 10 ETDRS letters in both groups of patients. Additionally, the therapy reduced total retinal NPA from 29 (14-36) mm2 to 12 (4-18) mm2 (Me (Q1-Q3); p<0.001) in patients with diagnosed nonperfusion. The effect of the therapy measured with vascular leakage, MA count, BCVArelative, and CSTrelative strongly depended on the zone of the retina and the NPA distribution. We conclude that the bevacizumab treatment had a positive effect on DME and BCVA in both study groups and on the size of retinal NPA in patients with retinal nonperfusion.http://dx.doi.org/10.1155/2021/6620122 |
| spellingShingle | Bogumiła Sędziak-Marcinek Sławomir Teper Elżbieta Chełmecka Adam Wylęgała Mateusz Marcinek Mateusz Bas Edward Wylęgała Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence Journal of Diabetes Research |
| title | Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence |
| title_full | Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence |
| title_fullStr | Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence |
| title_full_unstemmed | Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence |
| title_short | Diabetic Macular Edema Treatment with Bevacizumab Does Not Depend on the Retinal Nonperfusion Presence |
| title_sort | diabetic macular edema treatment with bevacizumab does not depend on the retinal nonperfusion presence |
| url | http://dx.doi.org/10.1155/2021/6620122 |
| work_keys_str_mv | AT bogumiłasedziakmarcinek diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT sławomirteper diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT elzbietachełmecka diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT adamwylegała diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT mateuszmarcinek diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT mateuszbas diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence AT edwardwylegała diabeticmacularedematreatmentwithbevacizumabdoesnotdependontheretinalnonperfusionpresence |